Avid Bioservices, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $782.44M
  • PE -5
  • Debt $53.57M
  • Cash $33.38M
  • EV $802.63M
  • FCF -$11.45M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$144.19M
EBIT-$18.97M
ROE-246%
ROA-6%
FCF-$11.45M
Equity$58.64M
Growth Stability-321%
PE-5.43
PEG-1.72
PB13.34
P/FCF-68.32
P/S5.5
Price/Cash0.04
Debt/Equity0.91
Debt/FCF-4.68
Net Margins-14%
Gross Margins6%
Op. Margins-13%
Earnings CAGR0%
Sales Growth YoY6%
Sales Growth QoQ-7%
Sales CAGR18%
FCF CAGR0%
Equity CAGR13%
Earnings Stability0
Earnings Growth YoY164%
Earnings Growth QoQ-96%
Earnings CAGR 5Y3%
Sales CAGR 5Y23%
FCF CAGR 5Y2%
Equity CAGR 5Y30%
Earnings CAGR 3Y10%
Sales CAGR 3Y10%
Equity CAGR 3Y4%
Market Cap$782.44M
Revenue$142.36M
Assets$334.64M
Total Debt$53.57M
Cash$33.38M
Shares Outstanding63.64M
EV802.63M
Earnings Score6%
Moat Score4%
Safety Score34%
Final Score15%
Working Capital32.54M
Current Ratio1.46
Gross Profit$8.93M
Shares Growth 3y1%
Equity Growth QoQ-4%
Equity Growth YoY-69%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

SEC Filings

Direct access to Avid Bioservices, Inc. (CDMO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Jul 31
    • 10-K Apr 30
    • 10-Q Jan 31
  • 2023
    • 10-Q Oct 31
    • 10-Q Jul 31
    • 10-K Apr 30
    • 10-Q Jan 31
  • 2022
    • 10-Q Oct 31
    • 10-Q Jul 31
    • 10-K Apr 30
    • 10-Q Jan 31

Sector Comparison

How does Avid Bioservices, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Avid Bioservices, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability 0%
loading chart...

Avid Bioservices, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Avid Bioservices, Inc..

= -$117M
012345678910TV
fcf-$11M-$11M-$12M-$12M-$12M-$12M-$12M-$12M-$12M-$12M-$12M-$119M
DCF-$10M-$9.5M-$8.7M-$7.9M-$7.2M-$6.6M-$6M-$5.5M-$5M-$4.6M-$46M
Value-$117M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years04/201504/201604/201704/201804/201904/202004/202104/202204/202304/2024TTM
Net Margins-202%-135%-57%-49%-17%-25%3%107%0%-101%-14%
ROA-3%1%-21%-7%-10%5%4%1%-6%-6%
ROE--120%-61%-48%-17%-36%4%73%0%-231%-246%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years04/201504/201604/201704/201804/201904/202004/202104/202204/202304/2024TTM
Debt over FCF-----02.174.55-2.97-0.54-2.6-4.68
Debt over Equity----00.11.250.80.260.890.91
Growth Stability--------1%-321%-321%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years04/201504/201604/201704/201804/201904/202004/202104/202204/202304/2024CAGR 5Y
Revenue YoY growth-67%29%-7%-0%11%61%25%25%-6%23%
Earnings YoY growth-11%-45%-19%-66%70%-122%4K%-100%-25K%3%
Equity YoY growth--15%7%4%-5%-21%86%125%9%-68%30%
FCF YoY growth-9%-16%-28%-56%-115%958%-320%93%-77%2%